# Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients

> **NCT02278276** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sulfagenix Australia Pty Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** sodium polysulthionate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02278276
- **Lead sponsor:** Sulfagenix Australia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-04
- **Final completion:** 2018-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2015-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278276, "Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02278276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*